Takeda Files For EU Approval For Biopress Blood-Pressure Replacement
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical seeks to market in Europe what it considers a key drug in its portfolio to replace its blockbuster Biopress (cilexetil) for treating high blood pressure